Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study

Background. Recombinant T-cell receptor ligand 1000 (RTL1000) is a single-chain protein construct containing the outer two domains of HLA-DR2 linked to myelin-oligodendrocyte-glycoprotein- (MOG-) 35–55 peptide. Analogues of RTL1000 induce T-cell tolerance, reverse clinical and histological disease,...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Yadav, Vijayshree, Bourdette, Dennis N., Bowen, James D., Lynch, Sharon G., Mattson, David, Preiningerova, Jana, Bever, Christopher T., Simon, Jack, Goldstein, Andrew, Burrows, Gregory G., Offner, Halina, Ferro, Al J., Vandenbark, Arthur A.
Format: Artigo
Jezik:Inglês
Izdano: Hindawi Publishing Corporation 2012
Teme:
Clinical Study
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3328144/
https://ncbi.nlm.nih.gov/pubmed/22548151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2012/954739
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki